TY - JOUR T1 - Generation of SIV resistant T cells and Macrophages from Nonhuman Primate Induced Pluripotent Stem Cells with Edited CCR5 locus JF - bioRxiv DO - 10.1101/2021.05.03.442446 SP - 2021.05.03.442446 AU - Saritha S. D’Souza AU - Akhilesh Kumar AU - Jason Weinfurter AU - Mi Ae Park AU - John Maufort AU - Lihong Tao AU - HyunJun Kang AU - Thaddeus Golos AU - James A Thomson AU - Matthew Reynolds AU - Igor Slukvin Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/05/04/2021.05.03.442446.abstract N2 - Adoptive therapies with genetically modified somatic T cells rendered HIV resistant have shown promise for AIDS therapy. A renewable source of HIV resistant human T cells from induced pluripotent stem cells (iPSCs) would further facilitate and broaden the applicability of these therapies. Here, we report successful targeting of the CCR5 locus in iPSCs generated from peripheral blood T cells (T-iPSCs) or fibroblasts (fib-iPSCs) from Mauritian Cynomolgus macaques (MCM), using CRISPR/Cas9 technology. We found that CCR5 editing does not affect pluripotency or hematopoietic and T cell differentiation potentials of fib-iPSCs. However, deletion of CCR5 in T-iPSCs leads to selective loss of their T cell redifferentiation potential without affecting myeloid development. T cells and macrophages produced from CCR5-edited MCM- iPSCs did not support replication of the CCR5-tropic simian immunodeficiency viruses SIVmac239 (T-cell tropic) and SIVmac316 (macrophage-tropic). Overall, these studies provide a platform for further exploration of AIDS therapies based on gene-edited iPSCs in a nonhuman primate preclinical model.Competing Interest StatementThe authors have declared no competing interest. ER -